Kesimpta for RRMS Now Available in Scotland at Low or No Cost

Kesimpta for RRMS Now Available in Scotland at Low or No Cost

299304

Kesimpta for RRMS Now Available in Scotland at Low or No Cost

Adults in Scotland with active relapsing-remitting multiple sclerosis (RRMS) will now have access at low or no cost to Kesimpta (ofatumumab), the first self-administered, at-home B-cell-targeting therapy for people with the neurodegenerative disease. The Scottish Medicines Consortium (SMC) recommended that the Novartis therapy be available through the country’s National Health System (NHS) to patients with active RRMS, defined by the presence of clinical relapses or imaging evidence of MS activity. “This is excellent news! The…

You must be logged in to read/download the full post.